Literature DB >> 34268573

Primary care provider perspectives on and utilization of a mandatory prescription drug monitoring program in New York City.

Alex Harocopos1, Bennett Allen1,2, Rachel Chernick1,3,4.   

Abstract

BACKGROUND: The ways in which prescription drug monitoring programs (PDMPs) have been integrated into primary care practice remain understudied, and research into physician utilization of PDMPs in states where PDMP use is mandated remains scant.
OBJECTIVES: To characterize primary care physician perspectives on and utilization of a mandatory PDMP in New York City.
METHODS: We conducted face-to-face, in-depth interviews with primary care physicians who reported that they currently prescribed opioid analgesic medication. We used a thematic analytic approach to characterize physician perspectives on the PDMP mandate and physician integration of mandatory PDMP use into primary care practice.
RESULTS: Primary care providers demonstrated a continuum of PDMP utilization, ranging from consistent use to the specifications of the mandate to inconsistent use to no use. Providers reported a range of perspectives on the purpose and function of the PDMP mandate, as well as a lack of clarity about the mandate and its enforcement.
CONCLUSION: Findings suggest a need for increased clinical and public health education about the use of PDMPs as clinical tools to identify and treat patients with potential substance use disorders in primary care.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved.For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Computers in medicine; opioid analgesic; prescription drug monitoring program; primary care; qualitative; substance use disorder

Mesh:

Substances:

Year:  2022        PMID: 34268573     DOI: 10.1093/fampra/cmab074

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  1 in total

1.  Family Practice substance use disorder theme issue: commentary.

Authors:  Mark Spigt; Jeffrey F Scherrer
Journal:  Fam Pract       Date:  2022-03-24       Impact factor: 2.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.